What Itraconazole Industry Experts Should Coach You On

For the 3 EGFR (+) patients, these parameters were 0%, 66.7%, 8 months and 13 months, respectively (Table III). No statistical differences in these parameters were identified between patients with or without the EGFR mutation status. Toxicity in the three therapy groups Toxicities are shown in Table IV. The most common toxicities were hematological, gastrointestinal and skin toxicities. Esophagitis and pulmonary toxicity were observed in a patient in the S-1-containing chemoradiotherapy group. No treatment-associated mortalities were recorded. Table IV. Adverse events of S-1 therapy. Uni-and multivariate analysis To identify the prognostic factors, uni- and multivariate analysis were analyzed using the variables below in the three therapy groups: Age (click here (IIIA-B, IV), number of rounds of prior chemotherapy (0�C1, ��2), ID (up to 100 mg, ��100 mg), ID/BSA (70 mg/m2 Verteporfin concentration or more, Itraconazole Discussion The availability of agents that target the EGFR tyrosine kinase has provided promising clinical benefits in specific subpopulations of NSCLC. At present, first- and second-generation EGFR-TKIs are available for clinical use. Even though a strong consensus exists on the use of EGFR-TKI as the treatment in patients with EGFR-mutated tumors, only ~10�C30% of patients with NSCLC have mutated EGFR (16,17). Therefore, platinum-based doublet chemotherapy continues to provide the standard of care for those patients with EGFR wild-type tumors or who have unknown EGFR status, and no clear differences were identified in OS between patients with or without the EGFR mutation status. In the present study, therefore, TTF and OS following S-1 therapy were evaluated, taking the EGFR mutation status into consideration for this purpose. S-1 was shown to produce an active response as a single agent for metastatic NSCLC with minimal toxicity (2,3,18). Kawahara et al (2) reported that S-1 monotherapy had an RR of 22%, median response duration, 3.4 months, and OS of 22%. As a second-line S-1 monotherapy, the RR, progression-free survival (PFS) and OS in two prospective phase II studies were 12.5%, 2.5 months, 8.2 months and 14%, and 4.2 months and 16.4 months, respectively (3,19). In addition, S-1 has been evaluated in the combined setting with cisplatin (CDDP) or carboplatin (CBDCA) (19,20).